Voyager Therapeutics, Inc. (VYGR) Operating margin 2016–2025
Voyager Therapeutics, Inc. (VYGR) operating margin by fiscal year — reported operating income divided by reported revenue.
-326.6%FY2025 · since FY2016: -290.4% → -326.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -326.6% | -222.4 pp |
| FY2024 | -104.1% | -152.9 pp |
| FY2023 | 48.8% | +173.1 pp |
| FY2022 | -124.3% | +72.5 pp |
| FY2021 | -196.8% | -212.8 pp |
| FY2020 | 16.0% | +65.5 pp |
| FY2019 | -49.5% | +1146.1 pp |
| FY2018 | -1195.6% | -486.6 pp |
| FY2017 | -709.1% | -418.6 pp |
| FY2016 | -290.4% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More VYGR financial trends
VYGR RevenueVYGR Net incomeVYGR Net marginVYGR Gross profitVYGR Gross marginVYGR Operating incomeVYGR Operating cash flowVYGR Free cash flowVYGR Capital expendituresVYGR Return on equityVYGR Stock buybacksVYGR Dividends paidVYGR Total assetsVYGR Total liabilitiesVYGR Shareholders’ equityVYGR overview →